Robert T. Heelan

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

William Pao, Vincent A. Miller, Maureen F. Zakowski et al. · Proceedings of the National Academy of Sciences · 2004 · 4.3K citations · Full text

Medicine, Molecular Genetics, Oncology +16

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

William Pao, Theresa Y. Wang, Gregory J. Riely et al. · PLoS Medicine · 2005 · 1.5K citations · Full text

Medicine, Oncology, Pharmacology +15

Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer

Vincent A. Miller, Mark G. Kris, Jyoti D. Patel et al. · Journal of Clinical Oncology · 2004 · 746 citations

Medicine, Oncology, Pharmacology +16

Screening for Early Lung Cancer

Myron R. Melamed, Betty J. Flehinger, Muhammad Zaman et al. · CHEST Journal · 1984 · 539 citations

Medicine, Oncology, Preventive Medicine +11

Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreas

Ephraim S. Casper, Mark R. Green, David P. Kelsen et al. · Investigational New Drugs · 1994 · 441 citations

Medicine, Oncology, Pharmacology +11